Member Login
Search

LUGPA Policy Brief: State Biomarker Testing Legislation

June 2026

At‑a‑Glance Essentials

What’s Changing Multiple states are advancing biomarker testing access bills requiring commercial insurers and Medicaid plans to cover evidence‑based molecular and genomic testing. Delaware SB 120, currently in the State Assembly, would mandate coverage for biomarker testing supported by FDA labeling, CMS policies, or nationally recognized clinical guidelines.

Why It Matters Biomarker testing is essential to modern urologic oncology. Standardized coverage ensures patients receive guidelines supported diagnostics that improve treatment selection, avoid ineffective therapies, and support precision cancer care.

Summary

Biomarker legislation expands access to clinically validated molecular and genomic tests by requiring coverage aligned with FDA labeling, CMS coverage policies, and evidence‑based guidelines such as NCCN. These bills address inconsistent payer policies, prior authorization delays, and gaps that limit access to precision medicine.

For urology, biomarker testing guides risk stratification, treatment selection, disease monitoring, and targeted therapy decisions for prostate, bladder, and kidney cancers. Clear, consistent coverage is critical for delivering guidelines concordant care in community settings.

Most state bills aim to:

  • Ensure coverage for validated guidelines supported tests
  • Reduce prior authorization barriers
  • Improve equity in access to precision medicine
  • Support value‑based care by avoiding ineffective treatments

Relevance to Independent Urology Practices

Biomarker legislation directly affects LUGPA practices by:

  • Improving patient access to precision diagnostics
  • Reducing administrative burden through clearer coverage rules
  • Aligning with value‑based care and targeted therapy pathways
  • Enhancing outcomes through earlier identification of aggressive disease
  • Advancing equity across payer types

LUGPA supports legislation that is evidence‑based, technology‑neutral, and flexible enough to keep pace with rapidly evolving science.

Conclusion

Biomarker testing legislation strengthens access to precision medicine and supports high‑quality cancer care in independent urology practices. LUGPA advocates for balanced policies—such as Delaware SB 120—that ensure coverage for validated tests, reduce administrative barriers, and preserve clinical decision‑making while supporting sustainable, community‑based specialty care.